EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Beyond Viral Control: Tenofovir's Hidden Impact on Blood–Brain Barrier Endothelial Cells

Saarah Behardien iD, Khayelihle Brian Makhathini iD, Chontrelle Willemse iD, David Fisher iD

Microcirculation · 2026-07 · 33 (5)

DOI: 10.1111/micc.70079 ↗

At a glance

Journal article in Microcirculation, published online on 2026-07-02. Written by Saarah Behardien and 3 co-authors. Institution: Neurobiology Research Group, Department of Medical Biosciences, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa. Major MEDLINE topics: Tenofovir, Blood-Brain Barrier, Endothelial Cells, Anti-HIV Agents. 35 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: University of the Western Cape Senate Research Funds, Thuthuka National Research Funding.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The blood–brain barrier (BBB) is a dynamic endothelial interface that protects the brain from harmful agents while regulating molecular exchange. Human immunodeficiency virus (HIV) compromises BBB integrity, promoting neurological damage. Antiretroviral (ARV) therapies suppress HIV replication, preventing immune system deterioration and progression to AIDS. Although Tenofovir‐based ARV regimens are vital for HIV treatment and prevention, their impact on cerebrovascular function remains unclear.

Aim

This study examined Tenofovir's effects on murine brain endothelial cells using an in vitro BBB model.

Methods

Brain endothelial cells (bEnd.5) were treated with Tenofovir Disoproxil Fumarate (TDF; 9.8–98 ng/mL) or Tenofovir Alafenamide (TAF; 1–10 ng/mL) for 24–96 h. Cell proliferation, cell cycle progression (via flow cytometry) and monolayer permeability (via Transendothelial Electrical Resistance) were evaluated.

Results

Both TDF and TAF treatments suppressed cell division by S‐phase disruption of the cell cycle and increased monolayer permeability.

Conclusion

These findings suggest that prolonged TDF or TAF exposure compromises BBB integrity by inhibiting endothelial cell division and altering barrier function, which could have implications for HIV‐ARV‐induced neurodegeneration in individuals receiving long‐term Tenofovir‐based therapy.

Subjects

MeSH terms (MEDLINE)

TenofovirBlood-Brain BarrierEndothelial CellsAnti-HIV AgentsAdenineAnimalsMiceHumansCell ProliferationCell LineCell CycleAlanine

Author keywords

TAFTDFblood–brain barrierhuman immunodeficiency viruspre‐exposure prophylaxissuppression

Substances

TenofovirAnti-HIV AgentsAdeninetenofovir alafenamideAlanine

Authors and institutions

  • Neurobiology Research Group, Department of Medical Biosciences, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa.

ORCID profiles: Saarah Behardien, Khayelihle Brian Makhathini, Chontrelle Willemse, David Fisher

Funding

  • University of the Western Cape Senate Research Funds
  • Thuthuka National Research Funding

Cite

APA

Behardien, S., Makhathini, K. B., Willemse, C., & Fisher, D. (2026). Beyond Viral Control: Tenofovir's Hidden Impact on Blood–Brain Barrier Endothelial Cells. Microcirculation, 33(5). https://doi.org/10.1111/micc.70079

Vancouver

Behardien S, Makhathini KB, Willemse C, Fisher D. Beyond Viral Control: Tenofovir's Hidden Impact on Blood–Brain Barrier Endothelial Cells. Microcirculation. 2026;33(5). doi:10.1111/micc.70079

BibTeX
@article{Behardien2026,
  author = {Behardien, Saarah and Makhathini, Khayelihle Brian and Willemse, Chontrelle and Fisher, David},
  title = {Beyond Viral Control: Tenofovir's Hidden Impact on Blood–Brain Barrier Endothelial Cells},
  journal = {Microcirculation},
  year = {2026},
  volume = {33},
  number = {5},
  doi = {10.1111/micc.70079}
}
Start for free →